Rementería-Capelo Laureano A, Lorente Pilar, Carrillo Virginia, Sánchez-Pina José M, Ruiz-Alcocer Javier, Contreras Inés
Clínica Rementería, Madrid, Spain.
Optics and Optometry Department, Universidad Complutense de Madrid, Madrid, Spain.
J Ophthalmol. 2022 Apr 28;2022:4659309. doi: 10.1155/2022/4659309. eCollection 2022.
To evaluate visual results and patient-perceived outcomes in patients with ocular pathologies implanted with a new extended depth-of-focus intraocular lens (IOL).
Patients with ocular pathology undergoing cataract surgery and bilaterally implanted with Vivity® IOLs were evaluated three months after surgery. The control group included patients with no ocular pathologies. Binocular defocus curves, corrected and uncorrected mono- and binocular distance visual acuity (DVA), and binocular contrast sensitivity were measured. Patients completed the Catquest-9SF questionnaire and reported on dysphotopsia and their need for spectacle-correction.
Twenty-five patients were included in each group. Monocular uncorrected DVA was better in the control group (-0.01 ± 0.07) compared with the study group (0.03 ± 0.08), =0.027. There were no other statistically significant differences in DVA, with an uncorrected binocular acuity of -0.06 ± 0.06 for the control group and -0.05 ± 0.06 for the study group. Binocular defocus curves were similar for both groups and there were no differences in contrast sensitivity values. Pooling the refractive results, 96% of eyes were within ±0.50 D of target refraction. Seventy percent of patients in the control group reported no halos, compared with 40% in the study group, =0.047. In both groups, 40% of patients reported being completely spectacle-independent, with the other 60% requiring glasses for near vision always or often. All patients reported being fairly or very satisfied with their vision.
Initial results of visual function after Vivity implantation in patients with ocular pathologies are encouraging, with high patient satisfaction and few difficulties for daily activities.
评估植入新型扩展焦深人工晶状体（IOL）的眼部疾病患者的视觉效果和患者主观感受。
对接受白内障手术并双侧植入Vivity® IOL的眼部疾病患者在术后三个月进行评估。对照组包括无眼部疾病的患者。测量双眼散焦曲线、矫正和未矫正的单眼及双眼远视力（DVA）以及双眼对比敏感度。患者完成Catquest-9SF问卷，并报告畏光情况及对眼镜矫正的需求。
每组纳入25例患者。与研究组（0.03±0.08）相比，对照组单眼未矫正DVA更好（-0.01±0.07），P = 0.027。DVA无其他统计学显著差异，对照组未矫正双眼视力为-0.06±0.06，研究组为-0.05±0.06。两组双眼散焦曲线相似，对比敏感度值无差异。综合屈光结果，96%的眼睛屈光在目标屈光度±0.50 D范围内。对照组70%的患者报告无光晕，研究组为40%，P = 0.047。两组中，40%的患者报告完全不需要眼镜，另外60%的患者总是或经常需要眼镜用于近视力。所有患者均报告对其视力相当满意或非常满意。
眼部疾病患者植入Vivity后的视觉功能初步结果令人鼓舞，患者满意度高，日常活动困难少。
